Patheon has entered a definitive agreement to acquire IRIX Pharmaceuticals, a company that specializes in difficult to manufacture Active Pharmaceutical Ingredients (APIs) for drugs from development through commercial launch. The transaction, subject to customary closing conditions, is expected to close in the next 60 days.   Patheon secures additional API development and manufacturing services in the U.S., including high-potency (OEL< 30ng/m3) and controlled substances (Schedule 1-4), bett...